Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:PULM OTCMKTS:RGRX NASDAQ:SBPH NASDAQ:UMRX NASDAQ:VTGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumePULMPulmatrix$4.94+0.8%$5.24$1.96▼$10.40N/A1.5725,595 shs13,410 shsRGRXRegeneRx Biopharmaceuticals$0.16+80,400.0%$0.03$0.00▼$0.16N/A4.6465 shs253 shsSBPHSpring Bank Pharmaceuticals$8.00$0.80▼$4.80$122.94M1.07177,606 shsN/AUMRXCogent Biosciences$12.72+2.9%$10.50$0.29▼$3.72$540.21M3.931.22 million shs1.27 million shsVTGNVistaGen Therapeutics$2.93-3.8%$3.03$1.90▼$3.88$89.74M0.55268,544 shs317,484 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformancePULMPulmatrix+0.20%-1.80%+6.06%-34.05%+131.13%RGRXRegeneRx Biopharmaceuticals0.00%+80,400.00%+80,400.00%+80,400.00%+11,400.00%SBPHSpring Bank Pharmaceuticals0.00%0.00%0.00%0.00%0.00%UMRXCogent Biosciences-1.44%-3.06%+2.06%+70.72%+17.49%VTGNVistaGen Therapeutics+4.83%-13.14%-4.10%+52.00%+1.67%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumePULMPulmatrix$4.94+0.8%$5.24$1.96▼$10.40N/A1.5725,595 shs13,410 shsRGRXRegeneRx Biopharmaceuticals$0.16+80,400.0%$0.03$0.00▼$0.16N/A4.6465 shs253 shsSBPHSpring Bank Pharmaceuticals$8.00$0.80▼$4.80$122.94M1.07177,606 shsN/AUMRXCogent Biosciences$12.72+2.9%$10.50$0.29▼$3.72$540.21M3.931.22 million shs1.27 million shsVTGNVistaGen Therapeutics$2.93-3.8%$3.03$1.90▼$3.88$89.74M0.55268,544 shs317,484 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformancePULMPulmatrix+0.20%-1.80%+6.06%-34.05%+131.13%RGRXRegeneRx Biopharmaceuticals0.00%+80,400.00%+80,400.00%+80,400.00%+11,400.00%SBPHSpring Bank Pharmaceuticals0.00%0.00%0.00%0.00%0.00%UMRXCogent Biosciences-1.44%-3.06%+2.06%+70.72%+17.49%VTGNVistaGen Therapeutics+4.83%-13.14%-4.10%+52.00%+1.67%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PricePULMPulmatrix 0.00N/AN/AN/ARGRXRegeneRx Biopharmaceuticals 0.00N/AN/AN/ASBPHSpring Bank Pharmaceuticals 0.00N/AN/AN/AUMRXCogent Biosciences 0.00N/AN/AN/AVTGNVistaGen Therapeutics 3.00BuyN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookPULMPulmatrix$7.81MN/AN/AN/A$2.45 per shareN/ARGRXRegeneRx Biopharmaceuticals$80KN/AN/AN/AN/AN/ASBPHSpring Bank PharmaceuticalsN/AN/AN/AN/A$2.16 per shareN/AUMRXCogent Biosciences$22.50M24.01N/AN/A$1.04 per share12.23VTGNVistaGen Therapeutics$646K138.91N/AN/A$2.44 per share1.20Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DatePULMPulmatrix-$6.94M-$2.17N/A∞N/A-122.46%-97.25%-88.96%11/6/2025 (Estimated)RGRXRegeneRx Biopharmaceuticals-$1.73MN/A0.00∞N/AN/AN/AN/AN/ASBPHSpring Bank Pharmaceuticals-$24.10M-$1.47N/AN/AN/AN/A-89.89%-52.89%N/AUMRXCogent Biosciences-$31.83M-$1.04N/AN/AN/A-96.84%-87.78%-52.14%N/AVTGNVistaGen Therapeutics-$51.42M-$1.78N/AN/AN/A-6,777.08%-74.06%-64.10%11/6/2025 (Estimated)Latest UMRX, SBPH, PULM, RGRX, and VTGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q1 2026VTGNVistaGen Therapeutics-$0.47-$0.47N/A-$0.47$0.22 million$0.24 million8/6/2025Q2 2025PULMPulmatrixN/A-$0.42N/A-$0.42N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthPULMPulmatrixN/AN/AN/AN/AN/ARGRXRegeneRx BiopharmaceuticalsN/AN/AN/AN/AN/ASBPHSpring Bank PharmaceuticalsN/AN/AN/AN/AN/AUMRXCogent BiosciencesN/AN/AN/AN/AN/AVTGNVistaGen TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioPULMPulmatrixN/A11.2111.21RGRXRegeneRx BiopharmaceuticalsN/AN/AN/ASBPHSpring Bank PharmaceuticalsN/A5.115.11UMRXCogent Biosciences0.182.902.90VTGNVistaGen TherapeuticsN/A5.985.98Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipPULMPulmatrix11.84%RGRXRegeneRx BiopharmaceuticalsN/ASBPHSpring Bank Pharmaceuticals17.17%UMRXCogent Biosciences26.39%VTGNVistaGen Therapeutics78.39%Insider OwnershipCompanyInsider OwnershipPULMPulmatrix0.62%RGRXRegeneRx Biopharmaceuticals12.60%SBPHSpring Bank Pharmaceuticals12.70%UMRXCogent Biosciences31.50%VTGNVistaGen Therapeutics2.85%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionablePULMPulmatrix20N/AN/ANot OptionableRGRXRegeneRx Biopharmaceuticals3N/AN/ANot OptionableSBPHSpring Bank Pharmaceuticals3017.27 millionN/ANot OptionableUMRXCogent Biosciences7242.47 millionN/ANot OptionableVTGNVistaGen Therapeutics4030.68 million29.81 millionOptionableUMRX, SBPH, PULM, RGRX, and VTGN HeadlinesRecent News About These CompaniesVistaGen Therapeutics, Inc. (NASDAQ:VTGN) Sees Significant Growth in Short InterestSeptember 16 at 8:37 AM | marketbeat.comVistagen to Present at the TD Cowen 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy SummitSeptember 9, 2025 | businesswire.comVistaGen Therapeutics, Inc. $VTGN Shares Bought by ADAR1 Capital Management LLCSeptember 4, 2025 | marketbeat.comVistagen Therapeutics, Inc. (VTGN) Eyes Breakthrough with Phase 3 Social Anxiety TrialSeptember 2, 2025 | sg.finance.yahoo.comWhile institutions invested in Vistagen Therapeutics, Inc. (NASDAQ:VTGN) benefited from last week's 11% gain, retail investors stood to gain the mostAugust 17, 2025 | finance.yahoo.comVistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q1 2026 Earnings Call TranscriptAugust 12, 2025 | msn.comVistagen Therapeutics Inc (VTGN) Q1 2026 Earnings Call Highlights: Advancing Key Trials Amid ...August 8, 2025 | finance.yahoo.comVistagen Therapeutics, Inc. (VTGN) Q1 2026 Earnings Call TranscriptAugust 8, 2025 | seekingalpha.comQ1 2026 Vistagen Therapeutics Inc Earnings Call TranscriptAugust 8, 2025 | gurufocus.comVistagen (VTGN) Q1 R&D Expense Jumps 54%August 7, 2025 | fool.comVistaGen Therapeutics, Inc. (VTGN) Reports Q1 Loss, Misses Revenue EstimatesAugust 7, 2025 | zacks.comVistagen Reports Fiscal Year 2026 First Quarter Financial Results and Corporate UpdateAugust 7, 2025 | businesswire.comVistaGen Therapeutics Q1 2026 Earnings PreviewAugust 6, 2025 | msn.comVistagen to Present at the BTIG Virtual Biotechnology ConferenceJuly 24, 2025 | businesswire.comVistagen Honored for Outstanding Workplace Culture and Mental Health LeadershipJuly 15, 2025 | businesswire.comVistagen Honored for Outstanding Workplace Culture and Mental Health LeadershipJuly 15, 2025 | businesswire.comStifel Maintains Buy on Vistagen Therapeutics, Inc. (VTGN) Despite PAL-4 DelayJuly 3, 2025 | msn.comVTGN Vistagen Therapeutics, Inc. - Seeking AlphaJune 27, 2025 | seekingalpha.comVistagen Appoints Elissa Cote as Chief Corporate Development OfficerJune 25, 2025 | businesswire.comVistagen Therapeutics, Inc. (VTGN) - Yahoo FinanceJune 24, 2025 | finance.yahoo.comVistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q4 2025 Earnings Call TranscriptJune 22, 2025 | insidermonkey.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeUMRX, SBPH, PULM, RGRX, and VTGN Company DescriptionsPulmatrix NASDAQ:PULM$4.94 +0.04 (+0.82%) As of 03:50 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.RegeneRx Biopharmaceuticals OTCMKTS:RGRX$0.16 +0.16 (+80,400.00%) As of 09/16/2025 10:07 AM EasternRegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of therapeutic peptide, Thymosin beta 4, for tissue and organ protection, repair, and regeneration. The company is developing RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease, or other pathology; RGN-352, an injectable formulation for the treatment of cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications; and RGN-137, a topical gel for the treatment of dermal wounds and reduction of scar tissue. It has strategic partnerships with Lee's Pharmaceutical Group and HLB Therapeutics. The company was formerly known as Alpha 1 Biomedicals, Inc. and changed its name to RegeneRx Biopharmaceuticals, Inc. in 2000. RegeneRx Biopharmaceuticals, Inc. was incorporated in 1982 and is based in Rockville, Maryland.Spring Bank Pharmaceuticals NASDAQ:SBPHSpring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for the treatment of a range of cancers and inflammatory diseases using its proprietary small molecule nucleotide platform. The company is developing SB 11285, a next-generation immunotherapeutic cyclic dinucleotide for the treatment of selected cancers; novel STING antagonist compounds for the treatment of autoimmune and inflammatory diseases; and novel platform to enable the targeted delivery of payload molecules. It has a collaboration agreement with with Roche to explore the co-administration of SB 11285. The company was formerly known as Spring Bank Technologies, Inc. and changed its name to Spring Bank Pharmaceuticals, Inc. in May 2008. Spring Bank Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Hopkinton, Massachusetts.Cogent Biosciences NASDAQ:UMRXCogent Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immunotherapy products designed to harness the power of a patient's immune system to cure cancer. The firm's technologies include Antibody-Coupled T-cell Receptor, which is a chimeric protein that binds to tumor targeting antibodies. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Cambridge, MA.VistaGen Therapeutics NASDAQ:VTGN$2.92 -0.12 (-3.78%) As of 03:51 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines. Its product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder. In addition, the company is also developing PH15, an early-stage investigational synthetic neuroactive steroid for the treatment of cognition improvement; PH80, an odorless and tasteless synthetic investigational pherine for the treatment of menopausal hot flashes and migraine; PH284, an early-stage investigational synthetic neuroactive steroid for the treatment of wasting syndrome Cachexia; and AV-101, an oral nmdr glycine site antagonist for depression and neurological disorders. Further, it has a license and collaboration agreement with EverInsight Therapeutics Inc. to develop and commercialize to address ophthalmologic and CNS disorders. The company was founded in 1998 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas FedEx Delivers Good News: The Bottom Is in for This Stock The Fed Cut Rates: What Now for the S&P 500 and Equity Markets? McDonald’s: New All-Time Highs Are Inevitable Workday Rising… To Fresh Record High Stock Prices 3 Reasons Amazon Could Be at an All-Time High by October Joby's Stock Is Quiet, But Its Commercial Engine Is In Overdrive NIO's New Dawn: Why Wall Street's Bullish Turn Signals a Comeback Eli Lilly’s Oral GLP-1 Breakthrough Could Change Everything Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
